布地格福治疗重度慢性阻塞性肺疾病的临床疗效研究

Clinical studies of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol in treating the severe chronic obstructive pulmonary disease

目的探讨布地格福治疗重度慢性阻塞性肺疾病的临床疗效。方法选取2021年11月~2022年5月经丰顺县人民医院呼吸内科收治的重度慢性阻塞性肺疾病患者100例,按照随机数字法将患者分为对照组和观察组,每组50例。对照组给予常规对症治疗,观察组在常规治疗的基础上给予布地格福吸入三联(ICS/LAMA/LABA),于入组后、治疗3个月及6个月后分别比较两组患者肺功能指标(FEV1、FVC、FEV1/FVC%)、6分钟步行试验、MRC评分、CAT评分差异。结果用药前,两组6MWT、MRC、CAT评分比较,差异无统计学意义(P>0.05);治疗3个月及6个月后,两组6MWT、MRC、CAT评分开始出现变化,至用药后6个月均较用药前有明显好转,其中观察组用药后3个月及6个月的MRC、CAT评分低于对照组,6MWT高于对照组,差异有统计学意义(P<0.05);用药前,两组FEV1、FVC、FEV1/FVC水平相比差异无统计学意义(P>0.05);治疗3个月后,两组FEV1、FVC、FEV1/FVC水平开始出现变化,至用药后6个月均较用药前有明显好转,其中观察组用药后3个月及6个月的FEV1、FVC、FEV1/FVC水平均高出对照组(P<0.05);不良反应发生率两组比较,差异无统计学意义(P>0.05)。结论布地格福治疗重度慢性阻塞性肺疾病的疗效显著,可有效改善患者的肺功能指标,提高其生活质量,用药安全性较佳,且使用单个吸入器代替多个单独的吸入器进行联合治疗,可大大提高治疗依从性和患者依从性,具有良好的经济效益和社会效益。

Objective To discuss the clinical efficacy of budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol in treating the severe chronic obstructive pulmonary disease(COPD).Methods 100 severe COPD patients treated from November 2021 to May 2022 in Fengshun County People’s Hospital were selected.According to random number table,patients were assigned to the control group(n=50)and the observation group(n=50).The control group took the symptomatic treatment;the observation group took the symptomatic treatment and ICS/LAMA/LABA.After treatment,3 m and 6 m of treatment,pulmonary function indicators like FEV1(forced expiratory volume in one second),FVC(forced vital capacity)and FEV1/FVC%,6-minute walk test,MRC(medical research council)and CAT(COPD assessment test)scores were compared.Results Before medication,6MWT,MRC and CAT scores between groups were not significantly different(P>0.05);after 3 m and 6 m of treatment,6MWT,MRC and CAT scores for two groups were significantly better than before;after 3 m and 6 m of treatment,MRC and CAT scores in the observation group were lower than those of the control group;6MWT scores were higher(P<0.05);before medication,FEV1,FVC and FEV1/FVC values between groups were not significantly different(P>0.05);after 3 m of treatment,FEV1,FVC and FEV1/FVC values for two groups were significantly better than before;FEV1,FVC and FEV1/FVC values in the observation group were even higher than those of the control group(P<0.05);the adverse event rate between groups was not significantly different(P>0.05).Conclusion Budesonide,glycopyrronium bromide and formoterol fumarate inhalation aerosol can improve the patient’s pulmonary function indicators,life quality and treatment safety;compared with multiple single inhalers,the single inhaler can improve the treatment compliance,economic and social benefits.